GlassScriptPhysician profile
Kimberly D Stewart
NPI 1184608739
$1,831.81
in general payments reported to CMS, 2019-2025
37 companies · $74.18 in 2025
The $74.18 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $530 · 2020: $199 · 2021: $307 · 2022: $264 · 2023: $341 · 2024: $117 · 2025: $74.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $247.26 | 2019-2023 | Lumakras |
| Eisai INC. | $145.78 | 2019-2024 | |
| Janssen Biotech, INC. | $142.22 | 2020-2025 | Tecvayli, Talvey, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $136.36 | 2019-2022 | |
| Intuitive Surgical, INC. | $91.98 | 2023 | Da Vinci Surgical System |
| Elekta, INC. | $69.33 | 2024 | Elekta Medical Linear Accelerator |
| Lilly USA, LLC | $66.23 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $62.85 | 2019-2021 | |
| Celgene Corporation | $62.53 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.02 | 2019-2023 | |
| Taiho Oncology, INC. | $59.87 | 2020-2023 | |
| Incyte Corporation | $58.31 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $57.39 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $46.04 | 2020-2021 | |
| Genzyme Corporation | $41.53 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $41.42 | 2019 | |
| Alexion Pharmaceuticals, INC. | $35.73 | 2019-2022 | |
| Pfizer INC. | $33.22 | 2019 | |
| Mylan Institutional INC. | $30.43 | 2019-2020 | |
| Seagen INC. | $29.08 | 2022-2023 | Tukysa |
| Jazz Pharmaceuticals INC. | $28.14 | 2019-2020 | |
| Sobi, INC | $26.48 | 2023 | |
| Dendreon Pharmaceuticals LLC | $24.84 | 2021 | |
| Boston Scientific Corporation | $24.04 | 2025 | Spaceoar Vue System - 10ml |
| Sumitomo Pharma America, INC. | $23.08 | 2023 | Orgovyx |
| Siemens Medical Solutions USA, INC. | $20.31 | 2025 | |
| Organogenesis INC. | $19.23 | 2021 | |
| Puma Biotechnology, INC. | $17.27 | 2019 | |
| Clovis Oncology, INC. | $16.89 | 2021 | |
| Myovant Sciences INC. | $16.12 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.66 | 2019 | |
| Dova Pharmaceuticals | $15.59 | 2021 | |
| Daiichi Sankyo INC. | $14.80 | 2022 | |
| Kyowa Kirin, INC. | $14.77 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $13.79 | 2019 | |
| Advanced Accelerator Applications | $11.92 | 2019 | |
| Foundation Medicine, INC. | $11.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.